- Home
- ANNX vs LPRO Comparison
ANNX vs LPRO Comparison
Compare ANNX & LPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANNX
- LPRO
- Stock Information
- Founded
- ANNX 2011
- LPRO 2000
- Country
- ANNX United States
- LPRO United States
- Employees
- ANNX N/A
- LPRO N/A
- Industry
- ANNX Biotechnology: Pharmaceutical Preparations
- LPRO Finance: Consumer Services
- Sector
- ANNX Health Care
- LPRO Finance
- Exchange
- ANNX Nasdaq
- LPRO Nasdaq
- Market Cap
- ANNX 668.8M
- LPRO 751.9M
- IPO Year
- ANNX 2020
- LPRO N/A
- Fundamental
- Price
- ANNX $5.14
- LPRO $6.47
- Analyst Decision
- ANNX Strong Buy
- LPRO Buy
- Analyst Count
- ANNX 7
- LPRO 7
- Target Price
- ANNX $15.80
- LPRO $6.80
- AVG Volume (30 Days)
- ANNX 1.4M
- LPRO 422.2K
- Earning Date
- ANNX 11-14-2024
- LPRO 11-07-2024
- Dividend Yield
- ANNX N/A
- LPRO N/A
- EPS Growth
- ANNX N/A
- LPRO N/A
- EPS
- ANNX N/A
- LPRO 0.04
- Revenue
- ANNX N/A
- LPRO $95,887,000.00
- Revenue This Year
- ANNX N/A
- LPRO N/A
- Revenue Next Year
- ANNX N/A
- LPRO $15.00
- P/E Ratio
- ANNX N/A
- LPRO $169.35
- Revenue Growth
- ANNX N/A
- LPRO N/A
- 52 Week Low
- ANNX $2.27
- LPRO $4.57
- 52 Week High
- ANNX $8.40
- LPRO $8.70
- Technical
- Relative Strength Index (RSI)
- ANNX 20.42
- LPRO 58.09
- Support Level
- ANNX $5.05
- LPRO $6.03
- Resistance Level
- ANNX $7.63
- LPRO $6.80
- Average True Range (ATR)
- ANNX 0.37
- LPRO 0.34
- MACD
- ANNX -0.23
- LPRO 0.00
- Stochastic Oscillator
- ANNX 3.68
- LPRO 60.18
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
About LPRO Open Lending Corporation
Open Lending Corp is engaged in providing automated lending services to financial institutions. The company offers loan analytics, risk-based pricing, risk modeling, and automated decision technology. Its Lenders Protection Program ("LPP") enables automotive lenders to make loans that are largely insured against losses from defaults.